Your AI-Trained Oncology Knowledge Connection!
An expert explains that real-world data from the REALiTEC study shows teclistamab remains highly effective in relapsed/refractory multiple myeloma—even among patients ineligible for clinical trials—demonstrating strong response rates, encouraging survival outcomes, and reinforcing the importance of therapy sequencing and broad access to bispecific antibodies in everyday clinical practice.
An expert explains that teclistamab has proven to be a highly effective and well-tolerated therapy for relapsed/refractory multiple myeloma in real-world settings, with outcomes mirroring clinical trials and improved infection management strategies enhancing its safety and accessibility for a broader range of patients.
An expert discusses that combining the bispecific antibodies teclistamab and talquetamab has shown promising efficacy and manageable toxicity in heavily pretreated multiple myeloma patients—including those with extramedullary disease—offering a compelling dual-targeted option for high-risk cases while allowing flexibility in sequencing for slower-progressing disease.
An expert explains that while bispecific antibodies show strong efficacy in relapsed/refractory multiple myeloma, optimizing their safety—through step-up dosing, infection prophylaxis, immunoglobulin support, and early symptom management—is essential to minimizing toxicity and expanding access to this promising treatment class.
An expert highlights that outpatient step-up dosing of bispecific antibody therapy in multiple myeloma is feasible and beneficial for selected patients—with criteria like caregiver support, proximity to care, and low disease burden—supported by prophylactic measures and close monitoring to ensure safety while improving patient comfort and reducing health care costs.
An expert explains that bispecific antibodies, currently approved for heavily pretreated multiple myeloma patients, are poised for earlier use—including maintenance and frontline settings—with ongoing research focused on safely stopping therapy after sustained minimal residual disease negativity to personalize treatment and improve long-term outcomes.
